Haleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fast-growing consumer healthcare market. The plant will produce oral-health products, including Sensodyne. It aims to reach one billion more consumers by 2030, with 300 million in India. The facility will also cater to export markets.

Haleon announces ₹2,000 crore investment to establish its first manufacturing facility in India, enhancing local oral care production and exports.

Haleon, the maker of Sensodyne, will invest £175 million to build its first oral health manufacturing plant in India, signaling strong confidence in the country's market potential.

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities

NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest about Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India, underscoring the…

Haleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fast-growing consumer healthcare market.…

NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest about Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India and South Asia, as the…